Covid-19 Drug: Europe in remdesivir crisis | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 24, 2022
TUESDAY, MAY 24, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Europe in remdesivir crisis

Coronavirus chronicle

Reuters
06 October, 2020, 09:00 pm
Last modified: 07 October, 2020, 12:28 am

Related News

  • Zelenskiy promises reciprocal rights for Poles in Ukraine
  • Four countries pledge tenfold rise in EU offshore wind power capacity
  • Money for Ukraine tops G7 agenda; inflation, food a concern
  • Monkeypox cases are on rise in Europe and US, here is why
  • EU clarifies how companies can legally pay for Russian gas

Europe in remdesivir crisis

The antiviral drug has been shown to shorten hospital recovery time in severe cases of Covid-19

Reuters
06 October, 2020, 09:00 pm
Last modified: 07 October, 2020, 12:28 am
An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues/ Reuters
An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues/ Reuters

 European countries are facing shortages of Covid-19 drug remdesivir because limited supplies are running out, officials said, with cases surging and the United States having bought up most of drugmaker Gilead's output.

In July, the 27 European Union countries and Britain, with a combined population of 500 million, secured doses to treat about 30,000 patients. The United States signed a deal for more than 500,000 courses of treatment, accounting for most of Gilead's output through September.

"Remdesivir has run out," Dutch Health Ministry spokesman Martijn Janssen told Reuters, adding however that new deliveries were expected shortly.

The antiviral drug has been shown to shorten hospital recovery time in severe cases of Covid-19. Remdesivir and the steroid dexamethasone are the only drugs authorised in Europe to treat Covid-19. Both have been given to US President Donald Trump, who is also receiving an experimental antibody cocktail.

Hospitalisations across Europe have been rapidly increasing, although in most countries still far below levels of the spring.

"Due to the increased hospital admissions, the demand for remdesivir is increasing rapidly," the Dutch spokesman said.

Poland's health minister Adam Niedzielski said on Tuesday the drug was in short supply in some hospitals. Its latest shipment from the EU order arrived just last Friday.

Spain, which has Europe's highest infection rate, experienced shortages in late August, its medicine agency said.

Britain, which has joined the EU procurement for remdesivir, has rationed its supply, prioritising Covid-19 patients who need it most, the health ministry said.

Shortages are likely to stir debate about the availability and pricing of Covid-19 drugs. While dexamethasone, a generic medicine, is widely available and cheap, remdesivir is protected by Gilead's patent.

The company has set a $2,340 price per patient for wealthier nations. It says it has also donated treatments for research and to treat hundreds of thousands of patients around the world.

NEW SUPPLIES

A spokesman for the European Commission, which negotiates medical supply deals on behalf of EU states during the pandemic, was not immediately available for a comment about shortages.

The EU executive is discussing with Gilead a new supply deal, meant to be sealed by late September or the beginning of October "to prevent a delivery gap," a Commission official told health experts from EU governments at a meeting in mid-September, minutes show.

The supplies secured so far by the EU were supposed to cover needs until the end of September. Several officials said new deliveries were expected shortly.

Gilead has expanded its production capacity. Last week it said it was meeting US demand and expected to cover global needs in October, even in the event of future surges of Covid-19.

Available doses in the EU have so far been divided according to the number of cases and hospitalisation rates. But not all EU states face shortages. Germany's health ministry said remdesivir stocks were sufficient for the coming months.

Top News

remdesivir / Europe

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image. Picture: Pixabay
    Govt raises regulatory duty to discourage imports of 200 products
  • Corporates go cashless…tax cut on cards
    Corporates go cashless…tax cut on cards
  • Photo: Collected
    Washington in touch with Dhaka on newly launched IPEF

MOST VIEWED

  • A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
    Pfizer says 3 Covid shots protect children under 5
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks
  • A person in personal protective equipment (PPE) walks a dog at a resident community, as the second stage of a two-stage lockdown has been launched to curb the spread of the coronavirus disease (Covid-19) in Shanghai, China April 3, 2022. REUTERS/Aly Song
    Shanghai reopens some public transport, still on high Covid alert
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Dynamic zero-Covid approach: China's choice to safeguard lives, underpin growth
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home

Related News

  • Zelenskiy promises reciprocal rights for Poles in Ukraine
  • Four countries pledge tenfold rise in EU offshore wind power capacity
  • Money for Ukraine tops G7 agenda; inflation, food a concern
  • Monkeypox cases are on rise in Europe and US, here is why
  • EU clarifies how companies can legally pay for Russian gas

Features

The balcony railings of the Boro Sardar Bari in Sonargaon. Made of cast iron, these railings feature vertical posts with intricate designs on top. Photo: Noor-A-Alam

The evolution of railing and grille designs

1h | Habitat
A Russian army service member fires a howitzer during drills at the Kuzminsky range in the southern Rostov region, Russia January 26, 2022. REUTERS/Sergey Pivovarov/File Photo

3 months of Ukraine war : Miscalculations, resistance and redirected focus

2h | Analysis
Musk is denying the sexual harassment allegation that surfaced this week. Photo: Bloomberg

Elon Musk’s crazily banal week 

20h | Panorama
Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

1d | Brands

More Videos from TBS

How to maintain a good relationship with colleagues

How to maintain a good relationship with colleagues

2h | Videos
Why are Duranta TV shows popular?

Why are Duranta TV shows popular?

15h | Videos
Donbas is hell, says Zelenskiy

Donbas is hell, says Zelenskiy

16h | Videos
Threat of Monkeypox on the horizon

Threat of Monkeypox on the horizon

17h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab